Public-Private Partnerships Like IMI Crucial to Industry's Future, Argue Leaders
Public-private partnerships like Europe's Innovative Medicines Initiative, the EU’s mechanism that promotes new treatment R&D, are crucial to the industry's future, according to Paul Stoffels, Chairman global R&D pharmaceuticals at Johnson & Johnson.
You may also be interested in...
The head of EFPIA believes drug makers are squandering opportunities offered by mobile health applications, a key point in the European trade body’s new manifesto.
Adaptive licensing is coming to Europe and, while it will be beneficial to patients, data exclusivity considerations may render it a double-edged sword to the innovative drug industry.
EFPIA’s call for more integration in approaches to some areas of health care ahead of the European Parliamentary elections in May could benefit research.